PAREXEL Named a FlexJobs Top 100 Company to Watch for Telecommuting and Remote Jobs in 2017
March 13 2017 - 9:00AM
Business Wire
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services organization, today announced
that it has been named to the FlexJobs Top 100 Companies to Watch
for Telecommuting and Remote Jobs in 2017 list for the fourth
consecutive year. The list recognizes companies that are
telecommuting-friendly, allowing for candidates to telecommute on a
full- or part-time basis.
PAREXEL offers approximately 20 percent of its nearly 20,000
global employees flexible work options, including telecommuting,
flexible schedules, and home-based employment. In North America,
approximately 40 percent of PAREXEL’s employees take advantage of
the Company’s telecommuting and flexible work opportunities. These
employees represent a diverse cross section of positions, including
clinical research, biostatistics, and regulatory affairs.
“We are pleased to be recognized as a leader in providing
telecommuting and remote job opportunities,” said Tom McGoldrick,
Corporate Vice President of Talent Acquisition, PAREXEL. “By
offering remote and flexible work options, PAREXEL has developed a
highly engaged, skilled, and satisfied workforce that allows us to
continue delivering for our clients and helping them bring new
treatments to patients in need.”
“More people are now professionally engaged in the knowledge
economy, which naturally supports jobs that can be done from home.
And as more companies embrace remote work in meaningful ways, more
people will have greater access to broader career and employment
opportunities, creating a positive ripple effect on our economy,”
said Sara Sutton Fell, founder and CEO of FlexJobs.
About the RankingFlexJobs, a job service specializing in
remote and flexible job opportunities, analyzed its database of
more than 47,000 companies’ job posting history in 2016 to
determine which companies posted the most remote-friendly job
opportunities throughout the last year. To be considered, companies
had to be telecommuting-friendly, either allowing for candidates to
telecommute entirely or part of the time. In 2017, PAREXEL was
included in the top third of the list.
About PAREXEL InternationalPAREXEL International
Corporation is a leading global biopharmaceutical services company,
providing a broad range of expertise-based clinical research,
consulting, medical communications, and technology solutions and
services to the worldwide pharmaceutical, biotechnology and medical
device industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, and
reimbursement. PAREXEL Informatics provides advanced technology
solutions, including medical imaging, to facilitate the clinical
development process. Headquartered near Boston, Massachusetts,
PAREXEL has offices in 85 locations in 51 countries around the
world, and had approximately 19,625 employees in the second
quarter. For more information about PAREXEL International visit
www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its affiliates.
All other trademarks are the property of their respective
owners.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170313005026/en/
Media:Dana RobieTel.: +1 781-434-4772Email:
Dana.Robie@PAREXEL.comorJenny Radloff, PAN CommunicationsTel: +1
617-502-4300Email: PAREXEL@pancomm.comorInvestors:Ronald
AldridgeTel.: +1-781-434-4753Email: ron.aldridge@PAREXEL.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Sep 2023 to Sep 2024